Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Remix Therapeutics Expand Data and Sequencing Collaboration

NEW YORK – Tempus AI and Remix Therapeutics have expanded a data and sequencing collaboration to include an analysis of adenoid cystic carcinoma (ACC) and acute myeloid leukemia (AML) cohorts using Tempus' Lens platform and to support a clinical trial of Remix's messenger RNA (mRNA) degrader REM-422, the companies said Tuesday.

REM-422 targets MYB, a transcription factor and oncogenic driver of some solid tumor and hematological malignancies, including ACC and AML. In the Phase I trial, Remix researchers are studying the safety and antitumor activity of REM-422 in patients with recurrent or metastatic ACC. Remix is using Tempus' xT Solid Tumor + Normal Match 648 gene DNA sequencing panel and xR whole transcriptome RNA sequencing panel with xM Monitor, Tempus' circulating tumor DNA assay, to support the trial.

The xT panel reports clinically relevant alterations; immunotherapy biomarkers including microsatellite instability and tumor mutational burden; HLA Class I genotyping; and potential germline alterations. The xR panel detects clinically relevant fusions for more than 100 targeted genes and altered splicing events for MET exon 14 and EGFRvIII. Remix will combine these assays with treatment response information on an exploratory basis within the trial.

Remix, which is headquartered in Cambridge, Massachusetts, is developing small molecule therapies that can selectively degrade RNA, enhance RNA expression, induce exon skipping, or rescue genetic lesions for cancer, central nervous system diseases, and rare conditions.